LUNDBECK
LUN
 Temps Différé - 12/08 16:59:32 |
|
| 33.35DKK | -0.86% |
Métier
| Santé | ||||
 | Recherche pharmaceutique et médicale | |||
| Produits pharmaceutiques | |||
| Produits pharmaceutiques | |||
| Pharmacies - Autres | |||
H. Lundbeck A/S est spécialisé dans le développement, la fabrication et la commercialisation de médicaments destinés au traitement des troubles psychiatriques et neurologiques (dépression, schizophrénie, syndrome de Lennox-Gastaut, maladie de Parkinson, maladie de Huntington, épilepsie, troubles de sommeil, etc.).
Nombre d'employés : 5 348 personnes.
Nombre d'employés : 5 348 personnes.
Ventes par activité
| 2020 | 2021 | ||||
| Brintellix/Trintellix | 3 102.00 | 17.6% | 3 526.00 | 21.6% | |
| Rexulti/Rxulti | 2 620.00 | 14.8% | 2 849.00 | 17.5% | |
| Other Pharmaceuticals | 2 738.00 | 15.5% | 2 439.00 | 15% | |
| Abilify Maintena | 2 271.00 | 12.9% | 2 420.00 | 14.8% | |
| Cipralex/Lexapro | 2 380.00 | 13.5% | 2 346.00 | 14.4% | |
| Northera | 2 553.00 | 14.4% | 665.00 | 4.1% | |
| Sabril | 777.00 | 4.4% | 657.00 | 4% | |
| Onfi | 642.00 | 3.6% | 505.00 | 3.1% | |
| Vyepti | 93.00 | 0.5% | 492.00 | 3% | |
| Reconciling Items | 491.00 | 2.8% | 347.00 | 2.1% | |
| Exceptional Items | 5.00 | 0% | 53.00 | 0.3% | |
| DKK en Millions | |||||
Ventes par région
| 2020 | 2021 | ||||
| United States | 9 074.00 | 51.3% | 7 456.00 | 45.7% | |
| International | 4 057.00 | 23% | 4 155.00 | 25.5% | |
| Europe | 3 299.00 | 18.7% | 3 469.00 | 21.3% | |
| North America | 716.00 | 4.1% | 789.00 | 4.8% | |
| Reconciling Items | 491.00 | 2.8% | 347.00 | 2.1% | |
| Exceptional Items | 5.00 | 0% | 53.00 | 0.3% | |
| Denmark | 30.00 | 0.2% | 30.00 | 0.2% | |
| DKK en Millions | |||||
Dirigeants
| Nom | Titre |
| Deborah L. Dunsire | President & Chief Executive Officer |
| Anders Götzsche | Chief Financial Officer & Executive Vice President |
| Lars Søren Rasmussen | Chairman |
| Lars Bang | Executive VP-Supply Operations & Engineering |
| Johan Luthman | EVP & Head-Research & Development |
| Tarek Samad | Senior Vice President & Head-Research |
| Rupert Sandbrink | Senior Vice President & Head-Clinical Development |
| Lene Skole-Sørensen | Deputy Chairman |
| Lars Erik Holmqvist | Independent Director |
| Henrik Sindal Jensen | Director |
| Actionnaires |
Coordonnées société
H. Lundbeck A/S
Ottiliavej 9
Valby, Capital Region 2500
Phone : +45.36.30.13.11
Fax : +45.36.30.19.40
Web : http://www.lundbeck.com/global
Ottiliavej 9
Valby, Capital Region 2500
Phone : +45.36.30.13.11
Fax : +45.36.30.19.40
Web : http://www.lundbeck.com/global
Secteur Pharmacies - Autres
| Var. 1janv | Capi. (M$) | ||
 | |||
| LUNDBECK | 0.00% | 4 691 | |
| |||
| JOHNSON & JOHNSON | -2.30% | 439 441 | |
| ELI LILLY AND COMPANY | 9.03% | 286 164 | |
| ROCHE HOLDING AG | -18.19% | 272 759 | |
| PFIZER, INC. | -18.22% | 271 020 | |
| ABBVIE INC. | 4.93% | 251 211 | |
| NOVO NORDISK A/S | 7.63% | 248 905 | |
| MERCK & CO., INC. | 16.04% | 225 285 | |
| ASTRAZENECA PLC | 21.06% | 198 807 | |
| NOVARTIS AG | 0.95% | 188 108 | |
| BRISTOL-MYERS SQUIBB COMPANY | 19.42% | 158 991 | |
| AMGEN INC. | 10.39% | 132 850 | |
| SANOFI | -4.32% | 109 570 | |
| GSK PLC | -14.82% | 69 216 | |
| DAIICHI SANKYO CO., LTD. | 24.17% | 52 442 | |
| BAYER AG | 9.96% | 52 428 | |
| CHUGAI PHARMACEUTICAL CO., LTD | 1.31% | 46 887 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | 20.56% | 44 046 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | -26.19% | 35 401 | |
| ASTELLAS PHARMA INC. | 7.70% | 27 725 | |
| ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD | -31.61% | 26 744 | |
Portefeuille de Marques
